🇺🇸 FDA
Patent

US 8911722

Modulation of yeast-based immunotherapy products and responses

granted A61KA61K2039/505A61K2039/523

Quick answer

US patent 8911722 (Modulation of yeast-based immunotherapy products and responses) held by The Regents of the University of Colorado, a Body Corporate expires Mon Dec 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado, a Body Corporate
Grant date
Tue Dec 16 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K2039/505, A61K2039/523, A61K2039/57, A61K36/06